Don't get left behind! The modernized is coming. Check it out now.
Say goodbye to!
The new site is coming soon - go to the modernized
Working… Menu

Desidustat in the Treatment of Anemia in CKD on Dialysis Patients (DREAM-D)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT04215120
Recruitment Status : Completed
First Posted : January 2, 2020
Last Update Posted : November 24, 2021
Information provided by (Responsible Party):
Zydus Lifesciences Limited

Brief Summary:
A phase 3, multicenter, open-label, randomized, active-controlled study to evaluate the efficacy and safety of Desidustat Tablet versus Epoetin alfa Injection for the treatment of anemia in patients with CKD on dialysis. (DREAM-D)

Condition or disease Intervention/treatment Phase
Chronic Kidney Disease Stage 5 on Dialysis Drug: Desidustat Oral Tablet Drug: Epoetin Alfa Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 392 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 3, Multicenter, Open-label, Randomized, Active-controlled Study to Evaluate the Efficacy and Safety of Desidustat Tablet Versus Epoetin Alfa Injection for the Treatment of Anemia in Patients With Chronic Kidney Disease (CKD) on Dialysis (DREAM-D)
Actual Study Start Date : January 4, 2020
Actual Primary Completion Date : September 2, 2021
Actual Study Completion Date : September 2, 2021

Arm Intervention/treatment
Active Comparator: Desidustat oral tablet
Randomly assigned to receive Desidustat 100 mg in a 1:1 ratio for 24 weeks.
Drug: Desidustat Oral Tablet
Desidustat tablet

Experimental: Epoetin Injection
Randomly assigned to receive Epoetin in a 1:1 ratio for 24 weeks.
Drug: Epoetin Alfa
Epoetin Injection

Primary Outcome Measures :
  1. Hemoglobin level [ Time Frame: 24 weeks ]
    Change in Hb levels from baseline

Secondary Outcome Measures :
  1. Hemoglobin Response [ Time Frame: 24 weeks ]
    No. of subjects with Hb response

  2. Hemoglobin target range [ Time Frame: 24 weeks ]
    Time to achieve target range Hb level

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

1. Ability to understand and give informed consent for participation. 2. Hemoglobin values during the screening period must be 8-11 g/dL (both inclusive).


  1. Patients will be considered not treated with erythropoietin analogue (Epoetin and Darbepoeitin) if they have not received erythropoietin analogue for at least 4 weeks and Mircera® for at least 8 weeks prior to screening visit. OR
  2. Patients who are on ESA therapy must be on stable dose for 4 weeks prior to enrollment (≤30% of dose change).

    4. Patients on hemodialysis (≥2 times in a week) for at least 12 weeks prior to screening visit and have access consisting of an arteriovenous fistula, AV graft, or catheter (permanent/temporary).

    5. Patients with no planned change in dialysis modality and with no planned renal transplant during study period.

    6. Left ventricular ejection fraction ≥40% by echocardiogram prior to randomization.

    7. No iron, folate or Vitamin B12 deficiency.

    8. Females of childbearing potential, must agree to use one of the approved contraception methods, from screening until completion of the follow-up visit.

    Exclusion Criteria:

    1. Red blood cell transfusion within 8 weeks prior to participating in the study.
    2. History of previous or concurrent cancer.
    3. Serologic status reflecting active hepatitis B or C infection or Human immunodeficiency virus (HIV) infection.
    4. Active infection at initiation of study.
    5. History of renal transplant.
    6. Uncontrolled hypertension (defined as SBP >180 mmHg or DBP >100 mmHg) at screening visit (before dialysis).
    7. Patient on high rhEPO dose at screening visit. [High dose defined as an epoetin dose of ≥450 IU/kg/week intravenous or ≥ 300 IU/kg/week subcutaneous or darbepoetin dose of ≥1.5 µg/kg/week subcutaneous].
    8. Major surgery within 90 days of the first day of study drug dosing, and minor surgery within 30 days of the first day of study drug dosing.
    9. Unable to swallow tablets or disease significantly affecting gastrointestinal function and/or inhibiting small intestine absorption such as; malabsorption syndrome, resection of the small bowel or poorly controlled inflammatory bowel disease affecting the small intestine.
    10. History of uncontrolled autoimmune hemolytic anemia, idiopathic thrombocytopenic purpura (ITP) or thalassemia.
    11. Presence or a history of bleeding disorders or clinical conditions (e.g. gastrointestinal [GI] bleeding or constitutional disorders) that may increase risk of life-threatening bleeding.
    12. History of stroke or intracranial hemorrhage within 6 months prior to enrollment.
    13. History of allergic reactions attributed to compounds of similar chemical or biologic composition to Desidustat or Epoetin alfa or to any erythropoieisis-stimulating agent.
    14. Pregnant and breastfeeding women.
    15. Current life-threatening illness, medical condition or organ system dysfunction which, in the Investigator's opinion, could compromise the patient's safety.
    16. Other laboratory abnormalities that, in the opinion of the investigator, would compromise the patient's safety or interfere with data interpretation.
    17. Presence of other clinically significant systemic disorders or diseases (e.g., respiratory, gastrointestinal, endocrine, immunological, dermatological, neurological, psychiatric disease or any other body system involvement) which, in the Investigator's opinion, could compromise the patient's safety.
    18. History of significant alcoholism or drug abuse within the past 1 year. History or presence of significant smoking (more than 10 cigarettes per day) or consumption of tobacco/nicotine products (more than 10 times per day).
    19. History of difficulty with donating blood.
    20. History or presence of any clinically significant electrocardiogram (ECG) abnormalities during screening.
    21. Participants who have participated in any drug research study other than the present trial within past 3 months.
    22. Participants who have donated one unit (350 ml) of blood in the past 3 months or history of whole blood transfusion in last 120 days prior to entry in the study.
    23. Existing clinically active chronic inflammatory disease (RA, Celiac disease, UC, Crohns disease)
    24. In case of DM patients, HbA1c >9%.
    25. Female volunteers with following criteria will not be recruited:

      • History of pregnancy or lactation in the past 3 months
      • Fertile female volunteers not protected against pregnancy by adequate long- term anti-fertility measures
      • History of less than 1 year of menopause and not using adequate long-term anti-fertility measures
      • Positive urine pregnancy test at Visit 2
      • Positive serum β-hCG level at the screening visit
    26. Currently active clinically significant cardiovascular disease such as uncontrolled arrhythmia, congestive heart failure, any class 3 or 4 cardiac disease as defined by the New York Heart Association Functional Classification or history of myocardial infarction prior to first dose with study drug.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04215120

Layout table for location information
Karnavati Hospital Pvt.Ltd
Ahmedabad, Gujarat, India, 380006
Shalby Hospital,
Ahmedabad, Gujarat, India, 380015
DHS Multispecialty Hospital
Ahmedabad, Gujarat, India, 380054
Chopda Medicare & Research Centre Pvt. Ltd
Nashik, Maharashtra, India, 422005
Aditya Birla Memorial Hospital
Pune, Maharashtra, India, 411033
Eternal Hospital
Jaipur, Rajasthan, India, 302017
Star Hospital
Hyderabad, Telangana, India, 500034
Sponsors and Collaborators
Zydus Lifesciences Limited
Layout table for investigator information
Study Director: Dr Deven Parmar, MD Zydus Lifesciences Limited
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Zydus Lifesciences Limited Identifier: NCT04215120    
Other Study ID Numbers: DESI.19.001.01
First Posted: January 2, 2020    Key Record Dates
Last Update Posted: November 24, 2021
Last Verified: January 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Kidney Diseases
Renal Insufficiency, Chronic
Urologic Diseases
Female Urogenital Diseases
Female Urogenital Diseases and Pregnancy Complications
Urogenital Diseases
Male Urogenital Diseases
Renal Insufficiency
Chronic Disease
Disease Attributes
Pathologic Processes
Epoetin Alfa